Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Topiroxostat (FYX-051) is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
10 mg | 在庫あり | ¥ 10,000 | |||
25 mg | 在庫あり | ¥ 15,000 | |||
50 mg | 在庫あり | ¥ 22,500 | |||
100 mg | 在庫あり | ¥ 39,000 | |||
200 mg | 在庫あり | ¥ 50,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,000 |
説明 | Topiroxostat (FYX-051) is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. |
ターゲット&IC50 | XOR:5.3 nM |
別名 | FYX-051 |
分子量 | 248.24 |
分子式 | C13H8N6 |
CAS No. | 577778-58-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (44.31 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Topiroxostat 577778-58-6 Immunology/Inflammation Metabolism P450 ROS Xanthine Oxidase CYPs Inhibitor Cytochrome P450 FYX051 hyperuricemia Asn 768 inhibit uric XOR acid FYX 051 pharmacokinetic FYX-051 CYP3A4 inhibitor